Karyopharm Therapeutics (FRA:25K) Total Liabilities : €343.5 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Total Liabilities?

Karyopharm Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €343.5 Mil.

Karyopharm Therapeutics's quarterly Total Liabilities declined from Sep. 2023 (€347.02 Mil) to Dec. 2023 (€345.38 Mil) and declined from Dec. 2023 (€345.38 Mil) to Mar. 2024 (€343.54 Mil).

Karyopharm Therapeutics's annual Total Liabilities increased from Dec. 2021 (€340.71 Mil) to Dec. 2022 (€353.84 Mil) but then declined from Dec. 2022 (€353.84 Mil) to Dec. 2023 (€345.38 Mil).

Karyopharm Therapeutics Total Liabilities Historical Data

The historical data trend for Karyopharm Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Total Liabilities Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

220.67

215.78

340.71

353.84

345.38

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															346.49	340.66	347.02	345.38	343.54

Karyopharm Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Karyopharm Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	63.712	+	(159.29	+	0.898
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	121.483	+	0)
	=	345.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	220.482	-	-124.901
	=	345.4

Karyopharm Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	60.114	+	(159.17	+	2.3750000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	121.881	+	0)
	=	343.5

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	188.101	-	-155.439
	=	343.5

Karyopharm Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines